Post-Marketing Surveillance of Herceptin Subcutaneous in Breast Cancer
Post-Marketing Surveillance of Herceptin Subcutaneous in Breast Cancer
This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous administration) per approved local labeling. Patients will be under observation according to standard of care in Korea.
Inclusion Criteria:
- All patients administered Herceptin SC for the locally approved indications
Exclusion Criteria:
N/A
Gyeongsangnam-do, 50612, South Korea
Gyeongsangnam-do, 52727, South Korea
Jeollanam-do, 58128, South Korea
Jeonlabuk-do, 54538, South Korea
Seoul, 01812, South Korea